CAS: 955881-01-3

PF-04279405 is a molecule that is being developed for the treatment of type 2 diabetes. PF-04279405 has been shown to reduce plasma glucose levels in diabetic patients and to improve insulin sensitivity. It also has a low risk of toxicity because it does not target glucose uptake into cells and does not cause any pancreatic toxicity in animal studies. Clinical trials have been conducted to assess the safety and efficacy of PF-04279405 in humans. In these trials, two-way crossover designs were used with the dose range of 100 mg to 400 mg per day. The clinical pathology study showed that PF-04279405 had no toxicities on heart function, cardiac electrical activity, or cardiac tissue structure. Regulatory endpoints were observed in healthy volunteers during these trials with no adverse events reported.

PF-04279405 is a potent and selective glucokinase activator.